Implantable hearing solutions company Cochlear
(ASX:COH) has obtained US Food and Drug Administration (FDA) approval for its Remote Check solution.
Remote Check is the first telehealth patient assessment tool, an at-home testing tool that allows people with a Cochlear™ Nucleus® 7 Sound Processor to complete a series of hearing checks from an app.
Cochlear will begin a controlled release of Remote Check in the US and intends to accelerate the release in Canada, the United Kingdom, and select countries in Western Europe.
Following increased demand for remote care due to the COVID-19 pandemic, the FDA expedited its approval.
Shares in Cochlear
(ASX:COH) are trading 0.87 per cent lower at $181.59.
